Datasets:

ESGBERT

/

base_data

like 2

in the development and recommendation of policies and management systems for environmental, health, safety and social responsibility matters to the Board.

at the Pharma Industry Awards, the most prestigious event in Ireland for our industry.

Plus, our College Park facility received “Best Workplace” from the Fingal Business Excellence and CSR Awards are doing to give back to the community, develop employees, sustain the environment and support patients.

BRIGHTER FUTURES | 42 WE ARE DRIVEN to help people fight rare, devastating diseases.

the complement system is dysregulated, it can lead to disease.

Often, these physicians have never encountered a specific rare disease, compounding the difficulty.

which is why Alexion is working to revolutionize the way rare diseases are diagnosed, not only for the conditions we treat but for a diverse set of diseases classified as rare.

leadership to be a long-term, strategic priority within the enterprise and ensures its role throughout the research and development pipeline.

Key competences include diagnostic test development and validation, data sciences, genetic testing, biobanking and go-to-market capabilities.

As the SmartPanel platform is further refined and validated, Alexion will share it through free licensing models to accelerate further research in pediatric rare-disease diagnosis.

Working for a broader societal benefit through our collaborations is a core value for Alexion.

accurate-diagnosis-of-rare-diseasesremains-difficult-despite-strong FASTEST DIAGNOSIS EVER Alexion was a core member of a team led by the Rady Children’s Institute for Genomic Medicine to set a Guinness World Record in 2018 for the fastest genomic-based diagnosis and turnaround of test results of a rare genetic disorder in a newborn, taking just 19 hours and 14 minutes.

For this accomplishment, Alexion’s Data Science team was recognized with the RARE Champion of Hope in Collaborations Award from Global Genes.

Work is underway to make this capability available to a broad range of hospitals.

BRIGHTER FUTURES | 43 In 2012, the 100,000 Genomes Project was established with the lofty goal of sequencing 100,000 whole genomes from samples from patients of Britain’s National Health Service (NHS) and combining the information with medical records.

This holds extraordinary opportunity to identify and create new treatments for people – especially children – with rare diseases, since at least diseases result from a defective gene(s)/genome(s)2.

The genomes of more than relatives of each patient, since most rare diseases are inherited.

As one of the first companies allowed access to the project’s data, Alexion has enabled the diagnosis of patients with nephronophthisis (NPH), a life threatening kidney disease that affects about one in every babies and usually results in kidney failure by age 15.

the information with their NHS clinical teams, who in turn were able to contact the patients and their physicians to finalize the diagnosis.

Our portfolio of four approved medicines (see Page for advancing the treatment of rare diseases.

• SOLIRIS® (eculizumab) for the treatment of NMOSD in adults in the United States, Europe and Japan.

SOLIRIS was previously approved for the treatment of PNH, aHUS and gMG.

Our discovery research programs aim to deliver life-changing therapies that bring hope to people living with rare disease.

Alexion has invested significantly in partnerships forged with other biotech companies that share our commitment to discovering and developing solutions for rare diseases.

a rare systemic disorder that results in progressive and widespread organ damage, most commonly to the heart and kidneys.

and there are no approved medicines to treat organs damaged by this devastating disease.

A/S, which is discovering and developing innovative peptide-based medicines.

co-administered with Halozyme's ENHANZE® drug-delivery technology, which aids in the dispersion and absorption of injected therapies, yielding a next-generation formulation called ALXN1810.

the potential to treat numerous additional complementmediated diseases and strengthening our pipeline portfolio of rare disease.

BRIGHTER FUTURES | 45 ADVANCING SHARED RESEARCH Externally Sponsored Research (ESR).

In addition to our internal research programs and direct collaborations, we support clinically and scientifically sound independent research to generate evidence and ultimately contribute to advancing patient care.

Through our ESR program, we receive, review and respond to unsolicited proposals from external sponsors requesting funding.

The global ESR program welcomes all qualified investigators interested in conducting independent research in complement-mediated and metabolic diseases.

focused on preclinical translation of scientific discoveries into therapies for rare disorders.

For example, we partner with Aarhus University in Denmark, home to leading experts on molecular structural biology of the complement components and their interactions.

We work with these experts to elucidate the molecular interactions between Alexion’s complement inhibitors and their targets.

Only data that cannot be identified back to individual trial participants is shared.

Qualified investigators can submit a proposal for access to our data and supporting documents to inform their future work.

our voluntary data sharing efforts from clinical studies.

ensuring compliance with all applicable laws, guidelines and standards.

Our voluntary data sharing efforts will uphold all regulations to protect patient privacy.

Voluntary data sharing activities are meant for informational purposes only and are not intended to promote any medicine or use.

to create brighter futures for all of our stakeholders, is an unwavering commitment to ethics and compliance.

Alexion’s Ethics and Compliance program is led by our Chief Compliance Off icer, Compliance Committee and Compliance team.

In principles applicable to all employees in a new structure and digital format.

The Code is in addition to more detailed company policies and procedures, as well as the geographyspecific policies and procedures.

It is the responsibility of every employee to read, understand and follow this Code, as well as all other company policies.

This Code is the foundation of Alexion’s overall program to ensure that all Alexion employees worldwide follow the appropriate standards and comply with all legal requirements in each country where we do business.

Alexion educates and trains employees on the Code through live training sessions, web-facilitated trainings and via online resources and training programs.

At Alexion, integrity is clearly defined as working first and foremost in the best interest of our patients.

In integrity underscores everything we do and how we embrace its foundational role in our daily work.

offers employees, business partners, customers and members of the public the opportunity to ask questions and/or report concerns about any potential misconduct or unethical behavior.

a secure online portal or via phone, or (not anonymously) through email.

metrics (see table on Page is to be a key influencer of compliance standards across the industry through ongoing, proactive thought leadership.

based compliance program into a robust, control-based program at the Society of Corporate Compliance & Ethics (SCCE) Compliance & Ethics Institute.

The SCCE is a member-based association for compliance and ethics professionals worldwide.

in the life sciences and medical devices industries.

ANTI-CORRUPTION POLICY Alexion has a zero-tolerance policy toward bribery and corruption.

to acting with the highest ethical standards in all countries where we conduct business.

which is now a part of our new employee onboarding.

The Alexion International Compliance team led throughout 2018 and 2019, reaching more than 2,200 employees in all of our markets globally.

serve as an extension of our global International Compliance team.

The program has an established governance structure to share insights, learnings and best practices.

The Board selects, oversees and monitors the performance of our Executive Committee, which is responsible for the day- to-day conduct of our business.

our Board is comprised of four committees: 2.

Committee During director attended fewer than 75% of the total number of meetings of the Board and the committees of the Board on which they served.

The Nominating and Corporate Governance Committee also has oversight of political activity and spending.

We publish a description of Board and management oversight of political spending on our website.

In adopted its Policy on Political Contributions and Lobbying Activity, which outlines our commitment to disclose semi-annually, among others: (i) corporate contributions to candidates in state and local elections as well as corporate contributions to other political committees, PACs and political party committees; (ii) contributions made by the Alexion Pharmaceuticals Inc. PAC; and (iii) the nondeductible portion of annual payments to trade associations receiving $25,000 or more in dues or payments in the year and corporate payments to other tax-exempt groups that may be used for election related purposes.

Shareholders who have general questions or concerns should contact our Investor Relations team.

to support the discovery, development and commercialization of life-changing therapies.

engaging in a manner that supports our patient focus and values.

OUR VENDOR CODE OF CONDUCT In suppliers in 2020.

All suppliers are required to read and acknowledge the Vendor Code of Conduct, which aims to ensure our suppliers share our commitment of high ethical standards and compliance with all applicable laws, regulations and other legal requirements in every country in which they operate.

Topics include anti-bribery/anti-corruption, privacy, animal welfare, fair labor and hiring practices, and environmental, health and safety.

standards for managing the purchase of goods and services.

Alexion strives to work with small businesses and small disadvantaged, women-owned and veteranowned small businesses where we are able.

Being an active sponsor of the Greater New England Minority Supplier Development Council.

GNEMSDC includes approximately businesses, covering Alexion’s signif icant U.S. operations in New Haven, Connecticut, and Boston, Massachusetts.

(Sustaining Our Planet) We have two Leadership in Energy and Environmental DesignTM (LEED®) buildings, one in New Haven, Connecticut, and one in Boston, Massachusetts.

Nominating and Corporate Governance Committee Charter governance body The Board receives education on a variety of topics, including CSR and governance.

Alexion also funds Board members’ attendance at relevant educational seminars, and Board members belong to the National Association of Corporate Directors (NACD).

sustainability reporting The Nominating and Governance Committee of the Board has oversight of Alexion’s CSR program and reviews Alexion’s CSR Report.

Redefine What it Means to Live With a Rare Disease, Page (Advancing Shared Research) 102-42 Identifying and selecting stakeholders We engage with a variety of stakeholders based on their genuine interest in Alexion and the biopharmaceutical industry and their potential to impact our business, our employees and the communities where we live and work.

102-49 Changes in reporting N/A - This is Alexion’s first CSR Report 102-50 Reporting period Calendar year 2019, which also serves as Alexion’s fiscal year.

102-52 Reporting cycle Alexion reports on an annual basis.

regarding the report [email protected] 102-54 Claims of reporting in accordance with the GRI Standards This report references disclosures from the GRI Standards 2018 and the SASB Biotechnology & Pharmaceuticals Industry, as detailed in this index.

Financial implications and other risks and opportunities due to climate change Other than potential risks associated with climate change to which any company might be exposed (e.g., extreme weather events, potential carbon taxes), Alexion’s business is not carbon intensive and any associated risk factors are minimal.

However, we practice design for the environment and aim for lean, efficient and sustainable operations in all new capital projects and operations.

MARKET PRESENCE Ratios of standard entry level wage by gender compared to local minimum wage Alexion operates in multiple locales and jurisdictions that have varying minimum-wage requirements, but employees’ starting salaries are typically well above applicable minimumwage requirements.

ANTI-COMPETITIVE BEHAVIOR Legal actions for anti-competitive behavior, anti-trust, and monopoly practices During the reporting period, Alexion was not identified as a participant in any legal actions alleging anti-competitive behavior or violations of anti-trust and monopoly legislation that rose to the level of materiality that would have required disclosure in our periodic reports filed with the SEC.

ENVIRONMENTAL COMPLIANCE laws and regulations During the reporting period, Alexion identified no noncompliance with environmental laws and/or regulations that rose to the level of materiality that would have required disclosure in our periodic reports filed with the SEC.

Percentage of employees receiving regular performance and career development reviews We strive to provide all employees with annual performance reviews.

We do not track the completion of career development reviews.

LOCAL COMMUNITIES Operations with local community engagement, impact assessments, and development programs Alexion participates in community engagement, impact assessments and development programs at the local level, based on local needs.

In Ireland, for example, we regularly engage with the Industrial Development Authority of Ireland; peer companies in the Dublin and as part of the Jobcare D15 Jobnet program; the Irish National Transport Authority on a Smarter Travel Program; the Institute of Technology Blanchardstown to sponsor technical students; and the Irish Business Employers Confederation to participate in several working groups for biopharma, pharma and chemical industries.

CUSTOMER HEALTH AND SAFETY Assessment of the health and safety impacts of product and service categories Patient safety is critical to Alexion.

We continually collect and analyze safety information on our medicines from many sources in a timely manner, and we work to ensure that patients, health care professionals and regulators have an optimal understanding of the benefits and risks of our medicines.

We are committed to regularly communicating to health care professionals and patients to help them make informed treatment choices.

Incidents of noncompliance concerning the health and safety impacts of products and services During the reporting period, Alexion identified no new incidents of noncompliance with regulations concerning the health and safety impacts of Alexion products and services that rose to the level of materiality that would have required disclosure in our periodic reports filed with the SEC.